# Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine

> **NCT05040789** · PHASE3 · WITHDRAWN · sponsor: **Medicago**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** CoVLP formulation

## Key facts

- **NCT ID:** NCT05040789
- **Lead sponsor:** Medicago
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-22
- **Primary completion:** 2022-05-31
- **Final completion:** 2022-05-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Further development terminated
- **Last updated:** 2023-06-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05040789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05040789, "Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05040789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*